Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed

Author:

Butler Mark S.12ORCID,Gigante Valeria3,Sati Hatim3,Paulin Sarah3,Al-Sulaiman Laila3,Rex John H.45,Fernandes Prabhavathi67,Arias Cesar A.89,Paul Mical1011,Thwaites Guy E.1213,Czaplewski Lloyd14,Alm Richard A.15ORCID,Lienhardt Christian16,Spigelman Melvin17,Silver Lynn L.18,Ohmagari Norio19,Kozlov Roman20,Harbarth Stephan2122,Beyer Peter3

Affiliation:

1. MSBChem Consulting, Brisbane, Queensland, Australia

2. Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia

3. Antimicrobial Resistance Division, WHO, Geneva, Switzerland

4. F2G Limited, Eccles, Manchester, United Kingdom

5. McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas, USA

6. Scientific Advisory Committee, GARDP, Geneva, Switzerland

7. The National Biodefense Science Board, U.S. Department of Health and Human Services, Washington, DC, USA

8. Center for Infectious Diseases Research, Houston Methodist Research Institute, Houston, Texas, USA

9. Center for Infectious Diseases, UTHealth School of Public Health, Houston, Texas, USA

10. Infectious Diseases Institute, Rambam Health Care Campus, Haifa, Israel

11. The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

12. Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam

13. Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, Oxford University, Oxford, United Kingdom

14. Chemical Biology Ventures Ltd., Abingdon, Oxfordshire, United Kingdom

15. CARB-X, Boston University, Boston, Massachusetts, USA

16. Université de Montpellier, INSERM, Institut de Recherche pour le Développement, Montpellier, France

17. TB Alliance, New York, New York, USA

18. LL Silver Consulting, Springfield, New Jersey, USA

19. National Center for Global Health and Medicine, Tokyo, Japan

20. Institute of Antimicrobial Chemotherapy, Smolensk State Medical University, Smolensk, Russia

21. National Center for Infection Prevention, Swissnoso, Bern, Switzerland

22. Infection Control Programme, Geneva University Hospitals and Faculty of Medicine, WHO Collaborating Center for Patient Safety, Geneva, Switzerland

Abstract

There is an urgent global need for new strategies and drugs to control and treat multidrug-resistant bacterial infections. In 2017, the World Health Organization (WHO) released a list of 12 antibiotic-resistant priority pathogens and began to critically analyze the antibacterial clinical pipeline. This review analyzes “traditional” and “nontraditional” antibacterial agents and modulators in clinical development current on 30 June 2021 with activity against the WHO priority pathogens mycobacteria and Clostridioides difficile .

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference100 articles.

1. An overview of the global antimicrobial resistance research and development hub and the current landscape

2. Global AMR R&D Hub. 2021. Estimating global patient needs and market potential for priority health technologies addressing antimicrobial resistance. https://globalamrhub.org/our-work/studies/market-potential-and-priority-patient-needs/. Global AMR R&D Hub Berlin Germany.

3. World Health Organization. 2017. WHO publishes list of bacteria for which new antibiotics are urgently needed. https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed. WHO Geneva Switzerland.

4. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

5. Confronting antimicrobial resistance beyond the COVID-19 pandemic and the 2020 US election

Cited by 138 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3